What is HC Wainwright's Forecast for RAPT Q2 Earnings?

RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) - Analysts at HC Wainwright issued their Q2 2025 earnings per share estimates for shares of RAPT Therapeutics in a research report issued on Thursday, May 22nd. HC Wainwright analyst E. Bodnar forecasts that the company will earn ($0.08) per share for the quarter. HC Wainwright has a "Strong-Buy" rating and a $6.00 price target on the stock. The consensus estimate for RAPT Therapeutics' current full-year earnings is ($2.14) per share. HC Wainwright also issued estimates for RAPT Therapeutics' Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.43) EPS, FY2026 earnings at ($0.61) EPS, FY2027 earnings at ($0.61) EPS, FY2028 earnings at ($0.60) EPS and FY2029 earnings at ($0.74) EPS.

A number of other research analysts also recently weighed in on the company. UBS Group cut their price target on RAPT Therapeutics from $2.00 to $1.00 and set a "neutral" rating on the stock in a research note on Thursday, May 22nd. Wall Street Zen upgraded RAPT Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, one has given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, RAPT Therapeutics has an average rating of "Hold" and a consensus price target of $3.00.

RAPT Therapeutics Price Performance

Shares of RAPT stock traded down $0.00 during trading hours on Monday, reaching $0.97. The company had a trading volume of 1,034,926 shares, compared to its average volume of 1,284,948. The company has a 50 day moving average of $0.98 and a 200 day moving average of $1.14. The firm has a market cap of $128.70 million, a price-to-earnings ratio of -0.35 and a beta of -0.04. RAPT Therapeutics has a 1-year low of $0.71 and a 1-year high of $4.60.

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.31) by $0.23.

Hedge Funds Weigh In On RAPT Therapeutics

Several hedge funds have recently modified their holdings of RAPT. Medicxi Ventures Management Jersey Ltd bought a new position in RAPT Therapeutics during the fourth quarter worth about $35,316,000. TCG Crossover Management LLC acquired a new stake in shares of RAPT Therapeutics in the fourth quarter valued at approximately $19,751,000. Orbimed Advisors LLC acquired a new position in RAPT Therapeutics during the fourth quarter valued at approximately $20,754,000. Foresite Capital Management VI LLC acquired a new position in shares of RAPT Therapeutics during the fourth quarter worth $19,750,000. Finally, RTW Investments LP acquired a new position in shares of RAPT Therapeutics during the fourth quarter worth $18,587,000. Institutional investors own 99.09% of the company's stock.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.